We are live on ! Find out more
LPCN icon

Lipocine

50 hedge funds and large institutions have $28.9M invested in Lipocine in 2017 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 16 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

37% more call options, than puts

Call options by funds: $430K | Put options by funds: $313K

6% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 16

0.31% less ownership

Funds ownership: 2.65%2.34% (-0.31%)

5% less capital invested

Capital invested by funds: $30.3M → $28.9M (-$1.42M)

14% less funds holding

Funds holding: 5850 (-8)

25% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 8

100% less funds holding in top 10

Funds holding in top 10: 10 (-1)

Holders
50
Holders Change
-8
Holders Change %
-13.79%
% of All Funds
1.24%
Holding in Top 10
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
New
6
Increased
17
Reduced
16
Closed
8
Calls
$430K
Puts
$313K
Net Calls
+$117K
Net Calls Change
-$43K
Name Holding Trade Value Shares
Change
Change in
Stake
Citigroup
51
Citigroup
New York
-$63.4K -978 -100%
Jacobs Levy Equity Management
52
Jacobs Levy Equity Management
New Jersey
-$49K -782 Closed
CS
53
Credit Suisse
Switzerland
-$38K -608 Closed
D.E. Shaw & Co
54
D.E. Shaw & Co
New York
-$38K -605 Closed
Group One Trading
55
Group One Trading
Illinois
-$19.2K -296 Closed
TRCT
56
Tower Research Capital (TRC)
New York
-$18.8K -290 Closed
SFS
57
Sowell Financial Services
Arkansas
-$4K -59 Closed
WAM
58
Wealthspire Advisors (Maryland)
Maryland
+$130 +2 New

LPCN Hedge Fund Activity: Q1 2017 in Review

50 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2017, worth a combined $28.9M — down 4.7% from $30.3M a quarter earlier.

Sellers outnumbered buyers: 8 funds closed out of LPCN and 6 opened new positions — a net loss of 2 holders — while 16 trimmed existing stakes and 17 added.

The largest buyer was BlackRock, adding an estimated $3.71M. The largest seller was Millennium Management, cutting an estimated $337K.

  • 50 institutional investors held Lipocine (LPCN) as of Q1 2017, down from 58 in Q4 2016.
  • Funds reported $28.9M of Lipocine stock for Q1 2017, down 4.7% quarter-over-quarter.
  • 6 funds opened new Lipocine positions in Q1 2017 and 8 closed out, a net change of -2 holders.
  • The largest Lipocine buyer in Q1 2017 was BlackRock, an estimated $3.71M added.
  • The largest Lipocine seller in Q1 2017 was Millennium Management, an estimated $337K sold.

Based on aggregated 13F filings for Q1 2017.